FDA Approves First-Ever Treatment for Deadly Hepatitis Delta Virus Infection
Bulevirtide becomes the first FDA-approved therapy for chronic HDV, a liver-destroying co-infection affecting millions worldwide.
Summary
The FDA has approved Hepcludex (bulevirtide) as the first-ever treatment for chronic hepatitis delta virus (HDV) infection. HDV only affects people already infected with hepatitis B and can rapidly cause liver scarring, liver cancer, and liver failure. In a phase 3 trial, 48% of patients on bulevirtide achieved a combined virologic and liver enzyme response at 48 weeks, versus just 2% in the delayed treatment group. By week 144, 50% of treated patients had undetectable HDV. Approved by Gilead Sciences under the FDA's Accelerated Approval pathway, this drug fills a long-standing treatment void for a serious, life-threatening condition that previously had no approved options in the United States.
Detailed Summary
Chronic hepatitis delta virus infection has long been one of the most dangerous and neglected liver diseases, causing faster progression to cirrhosis and liver cancer than hepatitis B alone. Until now, patients in the United States had no FDA-approved treatment. The approval of Hepcludex, or bulevirtide, marks a significant milestone in infectious disease and liver health management.
HDV is a unique virus that can only infect individuals who already carry hepatitis B virus. It is estimated to affect 15 to 20 million people globally. Risk factors include unprotected sex, intravenous drug use, and occupational blood exposure. Importantly, the hepatitis B vaccine also provides protection against HDV, making vaccination a key preventive strategy.
The approval was based on the MYR301 phase 3 trial, a multicenter randomized study in which patients received either immediate or delayed treatment with bulevirtide 8.5 mg daily. At 48 weeks, 48% of immediately treated patients achieved the combined endpoint of viral suppression and liver enzyme normalization, compared with only 2% in the delayed group. Rates of undetectable HDV RNA rose progressively from 20% at week 48 to 50% by week 144, suggesting durable and deepening responses over time.
For longevity-focused individuals, liver health is a foundational pillar. Chronic viral hepatitis accelerates fibrosis, promotes systemic inflammation, and dramatically increases liver cancer risk — all pathways that compress healthspan. Effective antiviral treatment that halts or reverses this damage has direct implications for long-term organ function and lifespan.
Caveats include the drug's boxed warning: abrupt discontinuation can trigger severe flares of both HDV and HBV. The trial was open-label, introducing potential bias, and long-term data beyond 144 weeks remain limited. This treatment is specifically indicated for adults without cirrhosis or with compensated cirrhosis only.
Key Findings
- Bulevirtide is the first FDA-approved treatment for chronic HDV infection, filling a critical care gap.
- 48% of treated patients achieved combined viral and liver enzyme response at 48 weeks versus 2% in controls.
- Undetectable HDV RNA rates climbed to 50% by week 144, suggesting deepening long-term viral suppression.
- HDV co-infection accelerates liver fibrosis and cancer risk; effective treatment directly protects healthspan.
- HBV vaccination prevents both hepatitis B and hepatitis D, offering a practical preventive strategy.
Methodology
This is an official FDA press release announcing regulatory approval, not a peer-reviewed research article. The efficacy data cited come from the MYR301 phase 3 randomized controlled trial, a credible evidence base. The open-label trial design is a minor limitation but the magnitude of benefit between groups is substantial.
Study Limitations
This press release summarizes trial outcomes without full peer-reviewed data; independent review of the MYR301 trial publication is advised. Long-term safety and efficacy data beyond 144 weeks are not yet available. The approval is limited to adults without cirrhosis or with compensated cirrhosis, excluding more advanced liver disease patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.